Algotec gains FDA nod for MediSurf Web product

Article

Algotec gains FDA nod for MediSurf Web productAlgotec of Raanana, Israel, has received Food and Drug Administration 510(k) clearance for its MediSurf software, a Java-based product for distributing medical images and clinical data over the

Algotec gains FDA nod for MediSurf Web product

Algotec of Raanana, Israel, has received Food and Drug Administration 510(k) clearance for its MediSurf software, a Java-based product for distributing medical images and clinical data over the Internet and intranets. Shipments have already begun via a worldwide OEM relationship with Elscint.

MediSurf customers employ a Java applet and a standard World Wide Web browser to access the MediSurf DICOM 3.0-compliant server, which is linked to both clinical image and data sources. There is no need for installation of additional hardware or software at end-user sites, according to the company.

Algotec debuted MediSurf at last year's Radiological Society of North America meeting. In addition to three beta sites in the U.S., Canada, and Germany, MediSurf has been installed at nine other institutions. Two MediSurf packages have been installed in the U.S.

Initially, Algotec will market MediSurf in the U.S. through OEMs. In a few months, however, the firm will sell MediSurf in the U.S. via regional distributors as well as through direct sales in some cases, said Kobi Margolin, Algotec marketing manager. Because the company expects OEMs to contribute most of MediSurf's sales, Algotec is actively looking for additional OEM relationships, Margolin said.

MediSurf could be the connectivity product that Elscint executives said their company would be releasing some time this year (PNN 7/97). Algotec executives declined to state whether MediSurf is that product, however, and Elscint executives were not available for comment.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.